Ariceum Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ariceum Therapeutics - overview
Established
2021
Location
Berlin, -, Germany
Primary Industry
Biotechnology
About
Founded in 2021 and based in Berlin, Germany, Ariceum Therapeutics operates as a radiopharmaceutical company that focuses on the diagnosis and precision treatment of neuroendocrine and aggressive and difficult-to-treat specific cancers. The company was launched in 2021 following the acquisition of all rights to its flagship product from subsequent shareholder, Ipsen. Ariceum Therapeutics has operations in Germany and is active across Europe, North America, and Australia. In March 2022, the firm raised EUR 25 million in series A funding co-led by investors EQT Life Sciences and HealthCap.
Ariceum as of January 2024, is led by CEO, Manfred Rüdiger. The company offers novel medicines for systemic targeted radiotherapy (STR) to visualize and treat cancer. Ariceum developed a proprietary peptide derivative, Satoreotide, a radiopharmaceutical drug and an antagonist of the somatostatin type 2 (SST2) receptor that is overexpressed in many cancers, including certain hard-to-treat cancers such as small cell lung cancer (SCLC), high-grade neuroendocrine tumors (NETs) and neuroblastoma, an aggressive, rare type of cancer that occurs mainly in young children. Satoreotide is used as a theranostic for both the diagnosis and treatment of tumors expressing the SST2 receptor.
The company's therapeutics pipeline includes SSO110 (NETs), SSO110 (SCLC), and SSO111 (SCLC).
Current Investors
Andera Partners, Earlybird , Pureos Bioventures
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals
Website
www.ariceum-therapeutics.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.